Literature DB >> 19778642

Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.

S Fogarty1, D G Hardie.   

Abstract

AMP-activated protein kinase (AMPK) is a cellular energy sensor activated by metabolic stresses that either inhibit ATP synthesis or accelerate ATP consumption. Activation of AMPK in response to an increase in the cellular AMP:ATP ratio results in inhibition of ATP-consuming processes such as gluconeogenesis and fatty acid synthesis, while stimulating ATP-generating processes, including fatty acid oxidation. These alterations in lipid and glucose metabolism would be expected to ameliorate the pathogenesis of obesity, type 2 diabetes and other metabolic disorders. Recently, AMPK has also been identified as a potential target for cancer prevention and/or treatment. Cell growth and proliferation are energetically demanding, and AMPK may act as an "energy checkpoint" that permits growth and proliferation only when energy reserves are sufficient. Thus, activators of AMPK could have potential as novel therapeutics both for metabolic disorders and for cancer, which together constitute two of the most prevalent groups of diseases worldwide. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778642     DOI: 10.1016/j.bbapap.2009.09.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  128 in total

1.  Protein kinase A contributes to the negative control of Snf1 protein kinase in Saccharomyces cerevisiae.

Authors:  LaKisha Barrett; Marianna Orlova; Marcin Maziarz; Sergei Kuchin
Journal:  Eukaryot Cell       Date:  2011-12-02

2.  Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.

Authors:  Xuxian Xiao; Qiongqiong He; Changming Lu; Kaitlin D Werle; Rui-Xun Zhao; Jianfeng Chen; Ben C Davis; Rutao Cui; Jiyong Liang; Zhi-Xiang Xu
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

Review 3.  Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning.

Authors:  Gregg L Semenza
Journal:  Biochim Biophys Acta       Date:  2010-08-21

Review 4.  Aging and TOR: interwoven in the fabric of life.

Authors:  Zelton Dave Sharp
Journal:  Cell Mol Life Sci       Date:  2010-10-21       Impact factor: 9.261

5.  Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death.

Authors:  Long Chen; Baoshan Xu; Lei Liu; Yan Luo; Hongyu Zhou; Wenxing Chen; Tao Shen; Xiuzhen Han; Christopher D Kontos; Shile Huang
Journal:  Free Radic Biol Med       Date:  2010-12-30       Impact factor: 7.376

6.  AMPK Inhibition Enhances the Neurotoxicity of Cu(II) in SH-SY5Y Cells.

Authors:  Ai-Ping Lan; Xian-Jia Xiong; Jun Chen; Xi Wang; Zhi-Fang Chai; Yi Hu
Journal:  Neurotox Res       Date:  2016-07-19       Impact factor: 3.911

7.  AICAR inhibits oxygen consumption by intact skeletal muscle cells in culture.

Authors:  Espen E Spangenburg; Kathryn C Jackson; Rosemary A Schuh
Journal:  J Physiol Biochem       Date:  2013-06-30       Impact factor: 4.158

8.  Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features.

Authors:  Elizabeth E Hopp; Stephanie M Cossette; Suresh N Kumar; Daniel Eastwood; Ramani Ramchandran; Erin Bishop
Journal:  Cancer Invest       Date:  2017-07-19       Impact factor: 2.176

9.  Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.

Authors:  Carolyne Bardeleben; Sanjai Sharma; Joseph R Reeve; Sara Bassilian; Patrick Frost; Bao Hoang; Yijiang Shi; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2013-04-12       Impact factor: 6.261

10.  Effects of excess corticosterone on LKB1 and AMPK signaling in rat skeletal muscle.

Authors:  G Nathan Nakken; Daniel L Jacobs; David M Thomson; Natasha Fillmore; William W Winder
Journal:  J Appl Physiol (1985)       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.